Source: Virtual Congress 2020 – What is hot in idiopathic pulmonary fibrosis?
Disease area: Interstitial lung diseases



Rating:

Share or cite this content

Citations should be made in the following way:
D. Jovanovic (Beograd, Republic of Serbia), M. Šterclová (Prague, Czech Republic), N. Mogulkoc (Izmir, Turkey), K. Lewandowsk (Warsaw, Poland), V. Müller (Budapest, Hungary), M. Hájková (Bratislava, Slovakia), M. Kramer (Petah Tikva, Israel), J. Tekavec-Trkanjec (Zagreb, Croatia), M. Studnicka (Salzburg, Austria), N. Stoeva (Sofia, Bulgaria), B. Jovovska Kaeva (Skopje), S. Littnerová (Brno, Czech Republic), M. Roksandic Milenkovic (Beograd, Republic of Serbia), M. Vasakova (Prague, Czech Republic). The effect of metformin on clinically relevant outcomes in 3,144 IPF patients from the EMPIRE registry. 1791

Member's Comments

No comment yet.

Related content which might interest you: Effect of metformin on clinically relevant outcomes in patients with idiopathic pulmonary fibrosis (IPF) Source: International Congress 2017 – ILDs: clinical aspects Year: 2017 A database for the follow-up of patients with IPF Source: Annual Congress 2008 - Management of idiopathic pulmonary fibrosis: what can we learn from the pathophysiology? Year: 2008 Top-10 comorbidities of symptomatic patients with moderate COPD in the clinical setting of the CRYSTAL study Source: International Congress 2016 – Features and impact of comorbidities in COPD Year: 2016 Stability of serum biomarkers and their associations with clinical outcomes in COPD patients and controls: a longitudinal study Source: Annual Congress 2009 - Biomarkers and biology in COPD Year: 2009 Comparison of LAMA/LABA vs ICS/LABA in high risk COPD patients: Pre-specified analysis on lung function and health status from the IMPACT trial Source: International Congress 2018 – COPD management Year: 2018 2-Year survival of patients with IPF with or without GERD: a study using VA national database Source: Virtual Congress 2020 – Clinical aspects of idiopathic pulmonary fibrosis Year: 2020 Gender differences in health status in patients with COPD: baseline characteristics of a multi-centre intervention and characterisation study on Seretide (COSMIC) Source: Eur Respir J 2002; 20: Suppl. 38, 262s Year: 2002 Correlation of response to antifibrotic treatment with adverse events to antifibrotic drugs in IPF patients from the real-world EMPIRE registry Source: Virtual Congress 2020 – Translational aspects of idiopathic pulmonary fibrosis Year: 2020 The effect of smoking on the treatment outcome in patients with pulmonary tuberculosis: A prospective cohort study Source: Annual Congress 2011 - Clinical tuberculosis Year: 2011 Effect of excluding ICU-admission on clinical outcomes in a randomized control trial studying the effect of corticosteroids in patients hospitalized with CAP Source: Annual Congress 2012 - Epidemiology: risk factors and prognosis in respiratory infections Year: 2012 A real life multicenter national study on the use of nintedanib in moderate to severe IPF patients Source: International Congress 2017 – IPF: from the bench to the bedside Year: 2017 An educational action for patients with COPD and its outcome Source: Annual Congress 2009 - Tobacco, bronchial tubes and the lung Year: 2009 Once-daily QVA149 provides clinically meaningful improvements in lung function and clinical outcomes Source: Annual Congress 2013 –Asthma and COPD drugs: efficacy, safety and pharmacoeconomics Year: 2013 Multi-institutional prospective cohort study of prognostic factors in patients with idiopathic pulmonary fibrosis receiving long-term oxygen therapy. Source: International Congress 2019 – The world of idiopathic pulmonary fibrosis Year: 2019 The effect of tiotropium in the treatment of patients with COPD Source: Annual Congress 2010 - COPD: management Year: 2010 A retrospective cohort study of patients with pulmonary embolism: the impact of comorbidities on patient's outcome Source: Eur Respir J 2016; 48: 555-557 Year: 2016 PROactive COPD, towards a patient reported outcome capturing physical activity in COPD Source: Annual Congress 2009 - EU Research Programmes. IMI: 1. U-BIOPRED asthma 2. PROactive COPD Year: 2009 COVID-19 risk and outcomes in adult asthmatics treated with biologics or systemic corticosteroids: nationwide real-world evidence. Source: Virtual Congress 2021 – Asthma treatment: clinical and translational science Year: 2021 Patterns of risk of death and asthma-related adverse outcomes in adult asthma patients receiving long-acting β2-agonist (LABA) therapy: results from the UK general practice research database (GPRD) Source: Annual Congress 2009 - Asthma treatment and control strategies in primary care Year: 2009 Efficacy of standard rehabilitation in COPD outpatients with comorbidities Source: Eur Respir J 2010; 36: 1042-1048 Year: 2010